Aulos Bioscience Provides Positive Interim Phase 1/2 Data From AU-007 at 2024 ASCO Annual Meeting
Preliminary results show durable anti-tumor activity in multiple solid tumor types among heavily pre-treated patients, including patients whose tumors have progressed... Read more.
TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
Durable survival effect observed in the largest prospective, non-interventional study completed examining TTFields therapy use in newly diagnosed GBM Topline data... Read more.
Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting
Emerging clinical pharmacokinetic and safety profiles of Bicycle Toxin Conjugates® demonstrate differentiation compared to antibody drug conjugates Trial-in-progress... Read more.
Stellar Bancorp, Inc. Declares Quarterly Dividend and New Share Repurchase Program
HOUSTON–(BUSINESS WIRE)–Stellar Bancorp, Inc. (the “Company”) (NYSE: STEL) today announced that on May 23, 2024, its Board of Directors declared... Read more.
Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer
83% (5/6) of patients achieved a confirmed partial response in cohort 1, the most mature dose level; one dose-limiting toxicity was observed, however, the dose level... Read more.
NMDP and CIBMTR to Present New, Promising Stem Cell Transplantation Trial Data using Mismatched, Unrelated Donors at 2024 ASCO Annual Meeting
Adults with blood cancers receiving peripheral blood stem cell transplant exhibited excellent survival rates and low incidence of life-threatening graft-versus-host-disease... Read more.
EMD Serono to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024
First-in-human data for potential first-in-class anti-CEACAM5 ADC with topoisomerase 1 inhibitor payload, M9140, in treatment of metastatic colorectal cancer to... Read more.
Federman & Sherwood Investigates Trionfo Solutions, LLC for Data Breach
OKLAHOMA CITY–(BUSINESS WIRE)–#FedermanSherwood–The law firm of Federman & Sherwood has initiated an investigation into Trionfo Solutions,... Read more.
Genworth Financial Announces Results of Annual Meeting
RICHMOND, Va.–(BUSINESS WIRE)–$GNW #genworth–Genworth Financial, Inc. (NYSE: GNW) announced the election of all nine director nominees at its 2024... Read more.
Genworth Financial Announces Results of Annual Meeting
RICHMOND, Va.–(BUSINESS WIRE)–$GNW #genworth–Genworth Financial, Inc. (NYSE: GNW) announced the election of all nine director nominees at its 2024... Read more.